Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minocin PK and Safety in Renal Insufficiency
NCT02808052Phase 1Terminated
- Sponsor
- Rempex Pharmaceuticals
- Start
- May 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of minocycline in bacterial infection, sponsored by Rempex Pharmaceuticals. Primary endpoints: Safety and Tolerability of Intravenous Dose(s) of Minocin (Minocycline) for Injection Assessed by Number of Subjects With Adverse Events at 24 weeks and Pharmacokinetics (PK) data. Started May 2017; status: terminated.
02
Drugs
minocycline
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT02808052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02808052.